Tag: survival

數據支持進一步評估試驗性的反義寡核苷酸 OT-101 (trabedersen) 作為胰臟導管腺癌中 TGFB2- 標靶治療方案的效果。

ALBUQUERQUE, New Mexico, July 16, 2025 (GLOBE NEWSWIRE) -- As the medical aesthetics industry continues to experience exponential growth, many medspa owners and aesthetic providers find themselves overwhelmed — juggling clients, marketing, operations, and still struggling to generate consistent profits. Dr. Kalpana Sundar, a board-certified physician and nationally recognized aesthetic business strategist, is on a mission to change that. This August, she is bringing her signature Aesthetic Profit Accelerator Bootcamp to Albuquerque, New Mexico, from August 7–10, 2025 — a powerful four-day intensive seminar designed to help aesthetic professionals turn passion into predictable, scalable profit.

Burlingame, CA, July 15, 2025 (GLOBE NEWSWIRE) -- The global Vitrification Market is estimated to be valued at USD 10.82 Bn in 2025 and is expected to reach USD 31.15 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 16.3% from 2025 to 2032. The vitrification market is witnessing growing demand due to its expanding applications in biobanking, assisted reproductive technologies, and cryopreservation of oocytes, embryos, and stem cells. This technique offers faster cooling rates and higher cell survival compared to conventional freezing, making it increasingly preferred in fertility clinics and research institutions. Market growth is also driven by advancements in cryoprotectant solutions and rising awareness of fertility preservation. Opportunities lie in emerging markets, technological innovations, and collaborations between biotech firms and healthcare providers to improve storage protocols and expand access to vitrification services.

New York City, NY, July 14, 2025 (GLOBE NEWSWIRE) --

The total network computing power exceeded the historical high of 900 EH/s, and the mining cost of each BTC soared 34% to $70,000-miners are looking for the survival code in the carnival and anxiety.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses IRobot (IRBT) To Contact Him Directly To Discuss Their Options

PHILADELPHIA and VANCOUVER, British Columbia, July 11, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced updated Phase 2 survival data for its lead immunotherapy candidate, Bria-IMT, in combination with an immune check point inhibitor (CPI).